AMRX vs CUBE · P/E 44, rev $2.79B vs P/E 25, rev $1.07B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the AMRX and CUBE stock pages for the full models.
Not investment advice.